Adaptimmune Therapeutics plc (473A) — Cash Flow Reinvestment Rate

Latest as of June 2024: 0.03x

Adaptimmune Therapeutics plc (473A) has a Cash Flow Reinvestment Rate of 0.03x as of June 2024, reinvesting €1.50 Million (capex €754.00K plus investments €-743.00K) from operating cash flow of €47.40 Million. Check earnings quality score of Adaptimmune Therapeutics plc to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.03x

(Capex + Investments) / Operating CF

Total Reinvested

€1.50 Million

Capex + Investments

Operating Cash Flow

€47.40 Million

EUR

Capital Expenditures

€754.00K

EUR

Adaptimmune Therapeutics plc Cash Flow Reinvestment Rate (2021–2021)

Historical reinvestment intensity for Adaptimmune Therapeutics plc across 1 annual periods. Explore Adaptimmune Therapeutics plc (473A) cash flow to debt to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Adaptimmune Therapeutics plc (2021–2021)

Year-by-year capital reinvestment analysis for Adaptimmune Therapeutics plc. For live market cap and broader valuation context, see Adaptimmune Therapeutics plc market cap and net worth.

Year	Reinvestment Rate	Total Reinvested (EUR)	Operating CF	Capex	YoY Change
2021	8.68x	€93.16 Million	€10.73 Million	€8.57 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow